NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

14th Meet The Professor

Advanced International Breast Cancer Course (AIBCC)

Padua (I), September 20th - 22nd 2018



11,2

points

 

  • Presentation
  • Poster session
  • Directors
  • Scientific Committee
  • Speakers & Chairmen
  • Program

Aims

Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. For these reasons, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the “classic” clinical specialties. Finally, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.

With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.
Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

This 14th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where opinion leaders and attendees will exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 14th AIBCC will award the 8th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. For the first time, we also welcome the presentation of posters from the participants and the bets poster will be awarded during the Award Cerimony.

We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

Addressed to

Physicians specialized in anatomical pathology, gynaecology and obstetrics, oncology, radiology, radiotherapy. Biologists, pharmacists and nurses.

It won’t be possible give credits to physicians specialized in different fields.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

University of Padua award for advances in breast cancer 2018

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.

Fellowships

Some fellowship (for under 40) will be awarded which will include registration and 3 Hotel nights. Those interested should send the registration form together with a short CV and a motivation letter within July 1st.
The organizing secretariat will confirm the award of the fellowship within July 20th and it will proceed with the organization of logistics.


Under 40

Free admission is available for 3 persons “under 40”. Registration forms will be accepted on a first-come, first-served basis unitil spaces are filled. The Organization Secretariat will confirm the registration by email.

CME

Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31)  will assign to the activity CME (31-228175): 11,2 CME points.

The credit certification is subject to:

  • Professions/specializations should correspond to those which have been accredited for CME;
  • 90% attendance to the meeting;
  • Completion of the meeting evaluation form;
  • Completion of the final questionnarie (at least 75% of correct answers).

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.

Participants can send one or more abstracts.

The form should be filled out by following specific guidelines:

  • Use the capitol letter for the title
  • Indicate each author's affiliation (that should include institution, department and town)
  • Underline the designated presenting author’s name.
  • Use font Times New Roman 10, single line spacing.

Abstracts will be selected by the Scientific Committee and will be shown during the poster session on September 22nd from 8 am. Poster size: 90 cm wide and 120 cm high (portrait).

People sending the selected abstracts will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement € 200,00 for Italian participants and € 300,00 for European participants).

Abstracts should be sent within September 10th. A confirmation will be sent by email within September 15th.

Download Form

Send abstract

Sorry, too late! Dead line was 09/10 2018!

Foto

Pier Franco Conte

Division of Medical Oncology 2

Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padua (I)

Foto

Gabriel N. Hortobagyi

Department of Breast Medical Oncology

The University of Texas - MD Anderson Cancer Center
Houston (USA)

Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)

Valentina Guarneri

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Jacek Jassem

Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston

NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Sibylle Loibl

German Breast Group
Department of Medicine and Research
University of Frankfurt (D)

Miguel Martin

Medical Oncology Service
Hospital Universitario Gregorio Marañon
Madrid (E)

Stefania Migliuolo

Europa Donna Italia
Milan (I)

Fedro Alessandro Peccatori

Department of Medical Oncology
European Institute of Oncology (IEO)
Milan (I)

Philip Poortmans

President of ESTRO; President-Elect of ECCO
Department of Radiation Oncology
Institut Curie
Paris (F)

Aleix Prat

Institute of Oncology (VHIO)
Vall d’Hebron- Institute of Oncology
Barcellona (E)

Matti S. Aapro

Multidisciplinary Oncology Institute
Clinique De Genolier
Genolier (CH)

Zora Baretta

Medical Oncology Unit AULS 8
Berica Distretto Ovest
Arzignano (I)

Giulia Valeria Bianchi

Medical Oncology Unit 1
IRCCS Istituto Nazionale Tumori
Milan (I)

Claudia Bozza

Medical Oncologi B
Oncology Center
Aviano (I)

Luisa Carbognin

Medical Oncology Unit
G.B. Rossi Hospital
Verona (I)

Francesca Caumo

Radiology Unit
Istituto Oncologico Veneto IRCCS
University of Padua (I)

Maria Vittoria Dieci

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Ingo Diel

Gynaecology Unit
Praxisklinik am Rosengarten
Mannheim (D)

Maia Dzhugashvili

Department of Radiation Oncology
Instituto Madrileño de Oncología (Grupo IMO)
Murcia (E)

Viviana E. Galimberti

Unit of Molecular Senology
European Institute of Oncology
Milan (I)

Marco Gambacciani

Obstetrics & Gynecology Unit
S. Chiara Hospital
Pisa (I)

Carlo Alberto Giorgi

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Michael Gnant

Department of Surgery
Medical University
Wien (A)

Gaia Griguolo

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Sylvia H. Heywang-Köbrunner

Reference Center Mammographie
Munchen (D)

Eleuterios Mamounas

MD Anderson Cancer Center Orlando
Comprehensive Breast Program
Orlando (F)

Caterina Marchiò

Pathology Unit
Candiolo Cancer Institute IRCCS
Candiolo (I)

Laura Marchioro

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Laura Martella

Medical Oncology
“S. Anna” Hospital
Ferrara, Cona (I)

Silvia Michieletto

Breast Surgery
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Mariateresa Nardi

Clinical nutrition and dietetics
Istituto Oncologico Veneto
Padova (I)

Enrico Orvieto

General Pathology and Cytopatology Unit
Department of Medicine-DIMED
University of Padua (I)

Giacomo Pelizzari

Medical Oncology
Oncology Center
Aviano (I)

Emanuela Romano

Cancer Immunotherapy Center
Institut Curie
Paris (F)

Hope Rugo

UCSF Carol Franc Buck Breast Care Center
Breast Oncology Clinical Trials Program
San Francisco (USA)

Tania Saibene

Breast Surgery
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Peter Schmid

Centre for Experimental Cancer Medicine Bart Cancer
Institute Queen Mary University
London (UK)

Thomas M.Suter

Gruppenleiter
Inselspital
Bern (E)

Sandra Swain M.

Washington Cancer Institute
Washington (USA)

Giulia Tasca

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

VassilenaTsvetkova

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Giuseppe Viale

Department of Pathology
European Institute of Oncology
University of Milan (I)

Stefania Zovato

Familial Cancer Clinic (Unità tumori ereditari)
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
Padova

Thursday, September 20th

8.30

Registration

9.15

Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi

 

SESSION I - EVOLUTION IN BREAST CANCER PREVENTION

Chairmen: Francesca Caumo, Stefania Zovato

9.30

Population screening vs risk-adapted surveillance
Sylvia Heywang – Kobrunner

9.50

Pharmacological prevention: how and whom?
Elefterios Mamounas

10.10

A look into the future: multigene panels
Gabriel N. Hortobagyi

10.30

Q&A

10.45

Coffee break

 

SESSION II - LOCOREGIONAL TREATMENT

Chairmen: Jacek Jassem, Gabriel N. Hortobagyi

11.15

Evolution in surgical management of the axilla
Viviana E. Galimberti

11.45

Do margins still matter for in situ and invasive lesions?
Elefterios Mamounas

12.15

Radiation therapy: what is the real target to aim at
Philip Poortmans

12.45

Q&A

13.00

Lunch

14.00

Multidisciplinary Tumor Board 1 – Locoregional treatment

  • Case 1: Locoregional relapse (questions: locoregional treatment with or without radiosensitisers (drugs; hyperthermia; EF)? “adjuvant” systemic treatment?) – Laura Martella
  • Case 2: Breast cancer in a patient previously treated with RT for Hodgkin disease (questions: locoregional treatment? contralateral mastectomy?) – Tania Saibene
  • Case 3: Healthy patient with familial history asking for risk-reducing mastectomy – Silvia Michieletto
  • Concluding comments – Jacek Jassem

 

SESSION III – SUPPORTIVE AND COMPLEMENTARY THERAPIES

Chairmen: Pier Franco Conte, Stefania Migliuolo

15.00

Diet: myths and facts
Mariateresa Nardi

15.20

Complementary therapies
Claudia Bozza

15.40

Scalp cooling
Laura Marchioro

16.00

Q&A

10.20

Coffee break

 

SESSION IV – LONG TERM CONSEQUENCES OF SYSTEMIC TREATMENTS

Chairmen: Hesham Ahmed Gaballah Elghazaly, Valentina Guarneri

16.40

Gynecologic
Marco Gambacciani

17.00

Cardiovascular and metabolic
Thomas Suter

17.20

Bone health
Ingo Diel

17.40

Q&A

18.00

Adjourn

Friday, September 21st

 

SESSION V – PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY

Chairmen: Enrico Orvieto, Peter Schmid

9.00

HER2 testing guidelines: new ASCO/CAP 2018
Giuseppe Viale

9.20

Molecular stratification of HER2+ and TNBC
Aleix Prat

9.40

Lobular breast cancer: a separate entity?
Caterina Marchiò

10.00

Q&A

10.20

Coffee Break

 

SESSION VI – NEW PATHWAYS AND NEW DRUGS

Chairmen: Sybille Loibl, Aleix Prat

10.50

Insights in resistance to CDK4/6 inhibitors
Stephen Johnston

11.10

Targeting the immune system: hopes and hypes
Peter Schmid

11.30

Combining radiotherapy and immunotherapy
Emanuela Romano

11.50

PARPi and other promising agents
Gabriel N. Hortobagyi

12.10

Q&A

12.30

Lunch

 

SESSION VII – SYSTEMIC TREATMENTS FOR EARLY BREAST CANCER

Chairmen: Stephen Johnston, Gabriel N. Hortobagyi

14.00

Extended adjuvant endocrine therapy: why? for whom? with what?
Michael Gnant

14.30

Risk adapted adjuvant treatment for HER2+ disease
Pier Franco Conte

15.00

Most promising ongoing trials in early disease
Hope Rugo

15.30

Q&A

16.00

Multidisciplinary Tumor Board 2 – Early Breast Cancer: challenging cases for pathologists and clinicians

  • Case 1: Rare histologies (pleomorphic lobular carcinoma, low aggressive triple negative histologies, micropapillary eyc) – Vassilena Tsvetkova
  • Case 2: HER2+ (de-escalated treatments for HER2+ disease) – Giulia Tasca
  • Case 3: Management of non pCR after neoadjuvant chemotherapy – Carlo Alberto Giorgi
  • Concluding comments – Maria Vittoria Dieci

17.00

Adjourn

17.30

Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2018 and best poster award

17.45

Lecture of the Awardee

18.15

Cocktail

19.30

Adjourn

Saturday, September 22nd

 

SESSION VIII – Advanced Breast Cancer

Chairman: Pier Franco Conte, Stephen Johnston

9.00

New therapeutic algorithms
HR+ disease - Sibylle Loibl
HER2+ disease - Valentina Guarneri
TN disease - Miguel Martin

10.30

Q&A

10.40

Coffee break

11.00

Do elderly patients require special management?
Matti Aapro

11.20

Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer
Chairman: Sandra Swain
Panelists: Giulia Valeria Bianchi, Jacek Jassem, Philip Poortmans, Hope Rugo

  • Case 1: Bone disease – Zora Baretta
  • Case 2: Brain mets – Gaia Griguolo
  • Case 3: Fulminat visceral disease – Luisa Carbognin
  • Case 4: Oligometastatic disease – Giacomo Pelizzari
  • Concluding comments – Sandra Swain

12.45

Adjourn and final evaluation questionnaire

Meeting Venue

Centro Convegni Papa Luciani, Via Forcellini 171, Padova.